| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS | REGISTER |
|
|
|
|
|||||||||||||
|
|
|||||||||||||||
a Department of
Medicine, Turku University, Finland, b Department of
Medical Microbiology, Turku University, c Department of Virology, Turku University, d Satalinna
Hospital, Finland, e Department of Medicine, Section of Rheumatology,
Tampere University Hospital, Finland, f Jyväskylä Central Hospital, Finland, g Stat-X, Finland
Correspondence to: Dr Timo Yli-Kerttula, Department of Medicine, Turku University, Kiinamyllynkatu 4-8, FIN-20520 Turku, Finland Email: timo.yli-kerttula{at}utu.fi
Accepted for publication 31 January 2000
BACKGROUND
Treatment
of reactive arthritis (ReA) with antibiotics has so far remained
controversial. Eradication of the causative microbe appears logical,
but short term antibiotic treatment has no beneficial effect on the
outcome of ReA.
OBJECTIVETo evaluate
the effect of a three month course of ciprofloxacin on ReA.
METHODSIn a
randomised, double blind, placebo controlled trial, between December
1992 and February 1996, 71 patients with acute ReA triggered by a
gastrointestinal or a urogenital infection were randomly assigned to
receive ciprofloxacin 500 mg or placebo twice daily for three months.
Patients were assessed at study entry, at 6 weeks, 3 months, 6 months,
and 12 months. Sixty two patients were valid for the efficacy analysis.
The primary outcome measures were erythrocyte sedimentation rate,
number of swollen joints, patients self assessment, and complete recovery.
RESULTSAdverse events
were mostly mild and occurred in both treatment groups. There were no
statistically significant differences in any of the primary or
secondary efficacy variables between the study groups at baseline or
during the 12 month follow up. All primary outcome measures indicated
that the condition of the patients improved during the study.
CONCLUSIONBoth groups
tended to recover. Ciprofloxacin, given as a three month course, had no
advantage over placebo treatment.
This article has been cited by other articles:
|
|
 |
|
  S S Hamdulay, S J Glynne, and A Keat When is arthritis reactive? Postgrad. Med. J., July 1, 2006; 82(969): 446 - 453. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T K Kvien, J S H Gaston, T Bardin, I Butrimiene, B A C Dijkmans, M Leirisalo-Repo, P Solakov, M Altwegg, P Mowinckel, P-A Plan, et al. Three month treatment of reactive arthritis with azithromycin: a EULAR double blind, placebo controlled study Ann Rheum Dis, September 1, 2004; 63(9): 1113 - 1119. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Colmegna, R. Cuchacovich, and L. R. Espinoza HLA-B27-Associated Reactive Arthritis: Pathogenetic and Clinical Considerations Clin. Microbiol. Rev., April 1, 2004; 17(2): 348 - 369. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T Yli-Kerttula, R Luukkainen, U Yli-Kerttula, T Mottonen, M Hakola, M Korpela, M Sanila, J Uksila, and A Toivanen Effect of a three month course of ciprofloxacin on the late prognosis of reactive arthritis Ann Rheum Dis, September 1, 2003; 62(9): 880 - 884. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K Laasila, L Laasonen, and M Leirisalo-Repo Antibiotic treatment and long term prognosis of reactive arthritis Ann Rheum Dis, July 1, 2003; 62(7): 655 - 658. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T Hannu, L Mattila, A Siitonen, and M Leirisalo-Repo Reactive arthritis following an outbreak of Salmonella typhimurium phage type 193 infection Ann Rheum Dis, March 1, 2002; 61(3): 264 - 266. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M Smieja, D W MacPherson, W Kean, M L Schmuck, C H Goldsmith, W Buchanan, L E Hart, and J B Mahony Randomised, blinded, placebo controlled trial of doxycycline for chronic seronegative arthritis Ann Rheum Dis, December 1, 2001; 60(12): 1088 - 1094. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS | REGISTER |
